Overview

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.
Phase:
Phase 1
Details
Lead Sponsor:
Rigel Pharmaceuticals
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions